Rabbit Anti-Human Lyve-1

Slide this table

Cat-Nr.102-PA50
Size200 µg
Price290 €
CategoryPolyclonal Antibody
Clone Nr.Rabbit IG
Species ReactivityHuman
Formulationlyophilized
BufferPBS
ReconstitutionCentrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.
Stability and StorageThe lyophilized antibody is stable at room temperature for up to 1 month. The reconstituted antibody is stable for at least two weeks at 2-8 °C. Frozen aliquots are stable for at least 6 months when stored at -20 °C.
PreparationProduced from sera of rabbits immunized with highly pure recombinant human soluble LYVE-1 produced in insect cells. The recombinant soluble LYVE-1consists of amino acid 24 (Ser) to 232 (Gly) and is fused to a C-terminal His-tag (6xHis). LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule co-localizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.
AntigenRecombinant human LYVE-1 (RT #S01-028)
ApplicationWB, IHC (P, F), IF
SynonymsLYVE1; HAR; XLKD1; LYVE-1; CRSBP-1
DescriptionLYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.
Uniprot IDQ9Y5Y7
Protein RefSeqNP_006682
mRNA RefSeqNM_006691

Figures


Protocol

Anti-human LYVE-1

a) For IF with LECPDF download
b) For FACSPDF download

 


Reference

  1. TGFβ counteracts LYVE-1-mediated induction of lymphangiogenesis by small hyaluronan oligosaccharides. Bauer J. et al., J Mol Med (Berl). 2018 Feb;96(2):199-209.
  2. Engineering Blood and Lymphatic Microvascular Networks in Fibrin Matrices. L. Knezevic et al., Front Bioeng Biotechnol. 2017; 5: 25.  
  3. ELM: A New, Simple, and Economic Assay to Measure Motility of Lymphatic Endothelial Cells. F. Torri et al., Lymphat Res Biol. 2017 Mar 1; 15(1): 39–44.
  4. Tissue-engineered 3D human lymphatic microvascular network for in vitro studies of lymphangiogenesis. Gibot L et al. Nat Protoc. 2017 May;12(5):1077-1088.
  5. Inflammation and Lymphedema Are Exacerbated and Prolonged by Neuropilin 2 Deficiency. P. Mucka et al., Am J Pathol. 2016 Nov; 186(11): 2803–2812.
  6. Orbital angiogenesis and lymphangiogenesis in thyroid eye disease: an analysis of vascular growth factors with clinical correlation. L. L. Wong et al., Ophthalmology. 2 16 Sep; 123(9): 2028–2036.
  7. Morphological and Molecular Characterization of Human Dermal Lymphatic Collectors. V. Hasselhof et al., PLoS One. 2016; 11(10): e0164964.  
  8. Understanding Lymphatic Drainage Pathways of the Ovaries to Predict Sites for Sentinel Nodes in Ovarian Cancer. M. Kleppe et al., Int J Gynecol Cancer. 2015 Oct; 25(8): 1405–1414.  
  9. Development of full-thickness human skin equivalents with blood and lymph-like capillary networks by cell coating technology. Matsusaki M. et al., J Biomed Mater Res A. 2015 Oct;103(10):3386-96.
  10. TGF-β1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxis. M-F Pang et al., Oncogene. 2016 Feb 11; 35(6): 748–760.
  11. Generation of pure lymphatic endothelial cells from human pluripotent stem cells and their therapeutic effects on wound repair. Shin-Jeong Lee et al., Sci Rep. 2015; 5: 11019.  
  12. Adhesion of Pancreatic Cancer Cells in a Liver-Microvasculature Mimicking Coculture Correlates with Their Propensity to Form Liver-Specific Metastasis In Vivo. M. M. Chowdhury et al., Biomed Res Int. 2014; 2014: 241571.  
  13. Arterial wall lymphangiogenesis is increased in the human iliac atherosclerotic arteries: involvement of CCR7 receptor. Grzegorek I et al. Lymphat Res Biol. 2014 Dec;12(4):222-31.
  14. Pivotal roles of lymphatic endothelial cell layers in the permeability to hydrophilic substances through collecting lymph vessel walls: effects of inflammatory cytokines. Kawai Y et al., Lymphat Res Biol. 2014 Sep;12(3):124-35.
  15. Molecular and Cellular Effects of In Vitro Shockwave Treatment on Lymphatic Endothelial Cells. S. Rohringer et al. PLoS One. 2014; 9(12): e114806.  
  16. Plasticity of Blood- and Lymphatic Endothelial Cells and Marker Identification. J. Keuschnigg et al., PLoS One. 2013; 8(9): e74293.  
  17. High density of peritumoral lymphatic vessels measured by D2-40/podoplanin and LYVE-1 expression in gastric cancer patients: an excellent prognostic indicator or a false friend?    J. Rudno-Rudzinska et al., Gastric Cancer. 2013; 16(4): 513–520.  
  18. Increased lymphatic vessel density and lymphangiogenesis in inflammatory bowel disease. Rahier JF et al., Aliment Pharmacol Ther. 2011 Sep;34(5):533-43.
  19. Lack of Evidence for the Direct Activation of Endothelial Cells by Adult Female and Microfilarial Excretory-Secretory Products. T. Weinkopff and Patrick Lammie, PLoS One. 2011; 6(8): e22282.  
  20. An exquisite cross-control mechanism among endothelial cell fate regulators directs the plasticity and heterogeneity of lymphatic endothelial cells. J. Kang et al. Blood. 2010 Jul 8; 116(1): 140–150.

All prices plus VAT + possible delivery charges